Status:
COMPLETED
Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Intraocular Inflammation
Eligibility:
All Genders
18+ years
Brief Summary
Faricimab (Vabysmo®), a novel pharmaceutical agent is a promising treatment for age-related macular degeneration and diabetic macular edema due to its dual mechanism of action, targeting both the VEGF...
Eligibility Criteria
Inclusion
- Inclusion criteria
- \>18 years of age
- Having received at least 1 intravitreal faricimab injection at our center
- Follow-up period of at least 6 weeks after the injection
- Exclusion criteria for IOI cases
- Having received intravitreal injections of other types (e.g., intravitreal steroids, antiviral agents) at the same time as the intravitreal anti-VEGF injection or during the follow-up period
- Underwent intraocular surgery within 6 weeks before or after the intravitreal injection, except for surgical interventions that are meant to diagnose or treat the actual IOI in question (e.g., diagnostic chamber tap, diagnostic vitrectomy, vitrectomy for suspected endophthalmitis, etc.)
Exclusion
Key Trial Info
Start Date :
November 10 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2025
Estimated Enrollment :
6053 Patients enrolled
Trial Details
Trial ID
NCT06902207
Start Date
November 10 2024
End Date
March 1 2025
Last Update
March 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Ophthalmology, Rigshospitalet
Glostrup Municipality, Denmark, 2600